Scibase

"Melanoma is the deadliest form of skin cancer and accounts for the majority of skin cancer deaths because it can spread from the skin to other parts of the body where it becomes difficult to treat and can be fatal. However, if caught early, melanoma is almost 100% curable.  For these reasons, we are looking forward to understanding how the Nevisense technology can help clinicians in the early detection of melanoma", said Alexander Meves, M.D., M.B.A, Professor of Dermatology, Mayo Clinic College of Medicine and Sciences.

"We are proud to work with the Mayo Clinic and believe this pilot represents an opportunity for SciBase to continue to address an unmet medical need by expanding access of the Nevisense test to more US patients at-point-of-care, when it is critical and makes a profound impact on patient care.", said Pia Renaudin, CEO of SciBase.

For additional information, please contact:
Pia Renaudin, CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com

Certified Advisor (CA):

Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se

About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.